TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CHICAGO, July 06, 2017 -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting, sorting and analyzing clinical and molecular data, will provide Moores Cancer Center at UC San Diego Health with molecular sequencing, analysis and decision support tools to enable further research on immune checkpoint inhibitors across cancer types.
“We are pleased to support Moores Cancer Center as it works to further incorporate genomic data into their clinical and research practice,” said Eric Lefkofsky, Co-founder and CEO of Tempus. “Collecting and analyzing patients' molecular, treatment and outcome data will be transformative for patients, researchers and the healthcare ecosystem.”
Moores Cancer Center is one of only 47 National Cancer Institute-designated Comprehensive Cancer Centers in the U.S. The center is committed to innovation, and is developing and testing the effectiveness of new therapies and medical devices in fields including personalized therapy, immunotherapy, minimally invasive surgeries, and more.
Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers.
About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.
Contact: Clo Ewing Director of Communications [email protected]
